\-\ Texto\\:\\ \ \(0\)\
\-\ prolactin\\ 794\\ ng\\/ml\ \(0\)\
\-\ the\\ patient\\ was\\ started\\ on\\ bromocriptine\\.\ \(0\)\
\-\ mri\\:\\ there\\ is\\ a\\ 1\\.6cm\\ cc\\ x\\ 1\\.4cm\\ transverse\\ x\\ 1\\.6cm\\ ap\\ expansile\\ mass\\ in\\ the\\ sella\\ turcica\\.\\ \\ the\\ mass\\ demonstrates\\ peripheral\\ enhancement\\,\\ with\\ a\\ central\\ fluid\\-fluid\\ level\\ best\\ appreciated\\ on\\ the\\ axial\\ t2\\ sequence\\.\ \(0\)\
\-\ prolactinoma\ \(4\)\
\-\ the\\ radiographic\\ examination\\,\\ laboratory\\ finding\\,\\ and\\ history\\ are\\ consistent\\ with\\ prolactinoma\\.\ \(0\)\
\-\ 27\\ yo\\ woman\\ presents\\ for\\ evaluation\\ of\\ her\\ amenorrhea\\.\\ \\ she\\ is\\ currently\\ taking\\ no\\ medication\\.\ \(0\)\
\-\ this\\ patient\\ bled\\ into\\ her\\ tumor\\ prior\\ to\\ pharmacotherapy\\,\\ and\\ was\\ fortunate\\ not\\ to\\ experience\\ pituitary\\ apoplexy\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ prolactinoma\\:\\ 0\\.3681932278708718\ \(0\)\
\-\ bled\\:\\ 0\\.19555635612022798\ \(0\)\
\-\ pharmacotherapy\\:\\ 0\\.19555635612022798\ \(0\)\
\-\ 794\\:\\ 0\\.18910256400780578\ \(0\)\
\-\ amenorrhea\\:\\ 0\\.1840966139354359\ \(0\)\
\-\ fortunate\\:\\ 0\\.1840966139354359\ \(0\)\
\-\ bromocriptine\\:\\ 0\\.1765482747280318\ \(0\)\
\-\ turcica\\:\\ 0\\.1609983735175723\ \(0\)\
\-\ her\\:\\ 0\\.15989724328796626\ \(0\)\
\-\ prolactin\\:\\ 0\\.15800276158688675\ \(0\)\
\-\ apoplexy\\:\\ 0\\.1553604446012716\ \(0\)\
\-\ sella\\:\\ 0\\.1324409602316874\ \(0\)\
\-\ sequence\\:\\ 0\\.1291113406617417\ \(0\)\
\-\ the\\:\\ 0\\.12767361913658185\ \(0\)\
\-\ experience\\:\\ 0\\.12725625411103808\ \(0\)\
\-\ cc\\:\\ 0\\.12395120602806436\ \(0\)\
\-\ taking\\:\\ 0\\.12395120602806436\ \(0\)\
\-\ medication\\:\\ 0\\.11827915730995824\ \(0\)\
\-\ pituitary\\:\\ 0\\.11804176075219514\ \(0\)\
\-\ expansile\\:\\ 0\\.11579651192624596\ \(0\)\
\-\ appreciated\\:\\ 0\\.11537322077661273\ \(0\)\
\-\ started\\:\\ 0\\.10779494992319051\ \(0\)\
\-\ 27\\:\\ 0\\.10370479089752309\ \(0\)\
\-\ best\\:\\ 0\\.10296919170602947\ \(0\)\
\-\ transverse\\:\\ 0\\.09859935611505481\ \(0\)\
\-\ currently\\:\\ 0\\.09830352195515729\ \(0\)\
\-\ mass\\:\\ 0\\.09776252281134082\ \(0\)\
\-\ radiographic\\:\\ 0\\.09494352033433154\ \(0\)\
\-\ laboratory\\:\\ 0\\.09292836342657501\ \(0\)\
\-\ ap\\:\\ 0\\.09187423423114925\ \(0\)\
\-\ peripheral\\:\\ 0\\.09150944952123737\ \(0\)\
\-\ was\\:\\ 0\\.08919787500438663\ \(0\)\
\-\ central\\:\\ 0\\.08545724896104868\ \(0\)\
\-\ finding\\:\\ 0\\.08411672087090541\ \(0\)\
\-\ patient\\:\\ 0\\.08324466784339005\ \(0\)\
\-\ examination\\:\\ 0\\.08188882892424577\ \(0\)\
\-\ yo\\:\\ 0\\.07994862164398313\ \(0\)\
\-\ evaluation\\:\\ 0\\.07804350483222536\ \(0\)\
\-\ level\\:\\ 0\\.0773015023966858\ \(0\)\
\-\ on\\:\\ 0\\.0772984907242049\ \(0\)\
\-\ she\\:\\ 0\\.07617770658131218\ \(0\)\
\-\ axial\\:\\ 0\\.07392028203437884\ \(0\)\
\-\ enhancement\\:\\ 0\\.07365751164666043\ \(0\)\
\-\ t2\\:\\ 0\\.07362488070947074\ \(0\)\
\-\ prior\\:\\ 0\\.07159964136141805\ \(0\)\
\-\ is\\:\\ 0\\.07009110515485559\ \(0\)\
\-\ consistent\\:\\ 0\\.06938846699102323\ \(0\)\
\-\ into\\:\\ 0\\.06802684049987069\ \(0\)\
\-\ tumor\\:\\ 0\\.06693592317034655\ \(0\)\
\-\ woman\\:\\ 0\\.0666473820175782\ \(0\)\
\-\ mri\\:\\ 0\\.06568862811313073\ \(0\)\
\-\ demonstrates\\:\\ 0\\.06429091741318595\ \(0\)\
\-\ to\\:\\ 0\\.06398467736483689\ \(0\)\
\-\ presents\\:\\ 0\\.06156034883128561\ \(0\)\
\-\ and\\:\\ 0\\.052887016407644205\ \(0\)\
\-\ there\\:\\ 0\\.05091900917878418\ \(0\)\
\-\ not\\:\\ 0\\.05051965411870719\ \(0\)\
\-\ with\\:\\ 0\\.05011639279364781\ \(0\)\
\-\ history\\:\\ 0\\.04889208590062718\ \(0\)\
\-\ are\\:\\ 0\\.04855893164562472\ \(0\)\
\-\ this\\:\\ 0\\.043972920328603955\ \(0\)\
\-\ no\\:\\ 0\\.04161450500332465\ \(0\)\
\-\ for\\:\\ 0\\.03878683405074467\ \(0\)\
\-\ in\\:\\ 0\\.03183487245768199\ \(0\)\
\-\ of\\:\\ 0\\.025043233071031436\ \(0\)\
